BioVersys Shareholders Approve All Board Proposals at Annual General Meeting
April 30th, 2026 8:08 PM
By: Newsworthy Staff
BioVersys AG announced that shareholders voted in favor of all proposals at the Annual General Meeting, including re-election of board members and approval of financial statements, as the company progresses its lead candidate BV100 into Phase 3 trials.
BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial treatments for multi-drug resistant (MDR) infections, announced today that all proposals by the Board of Directors were approved by shareholders at the Annual General Meeting. The approvals include the 2025 Annual Report, financial statements, and the re-election of key board members.
Dr. Seng Chin Mah, Chairman of the Board of Directors, expressed gratitude for shareholder support, emphasizing the company's focus on advancing its lead candidate BV100, which achieved First Patient First Visit (FPFV) for its global Phase 3 trial. "Having achieved FPFV for the global BV100 Phase 3 trial, we are completely focused on eventually bringing this therapeutic option to patients in dire need," said Dr. Mah. He also acknowledged the contributions of outgoing board member Dr. William Jenkins and welcomed new member Ms. Simona Skerjanec.
Shareholders approved the re-election of Seng Chin Mah as Chairman, along with the re-election of David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Ms. Simona Skerjanec was elected as a new Member of the Board of Directors. Additionally, the maximum aggregate compensation for the Board of Directors until the 2027 AGM and for the Executive Committee for the financial year 2027 were approved.
The company's pipeline includes BV100 for Acinetobacter baumannii infections (Phase 3) and alpibectir for tuberculosis (Phase 2, in collaboration with GlaxoSmithKline). The approved annual report and AGM documents are available on the company's website at Annual Report and AGM.
BioVersys is a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by MDR bacteria. The company uses two internal technology platforms (TRIC and Ansamycin Chemistry) to develop candidates that overcome resistance mechanisms and block virulence production. This addresses the high unmet medical need for new treatments against resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
